Production (Stage)
ArriVent BioPharma, Inc.
AVBP
$20.40
-$0.23-1.12%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -70.91% | -16.09% | -38.35% | -33.85% | -78.72% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 258.49% | 258.44% | 273.73% | 229.23% | 175.76% |
| Change in Net Operating Assets | -80.74% | -43.89% | 782.08% | 20.30% | 250.86% |
| Cash from Operations | -107.66% | -25.73% | -21.40% | -32.69% | -11.60% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 200.00% | 200.00% | -- |
| Cash from Investing | -- | -- | 200.00% | 200.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.83% | 52,606.50% | 222,294.05% | 413,942.22% | 442,661.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -100.00% | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 97.93% | -- | -25.19% | -- | -- |
| Cash from Financing | -95.80% | 335.34% | 20.72% | 18.90% | -0.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -312.44% | -486.12% | 97.01% | 79.71% | -5.38% |